Misoprostol and pregnancy.
Goldberg
A B
AB
Department of Obstetrics, Gynecology, and Reproductive Sciences, Center for Reproductive Health Research and Policy, San Francisco General Hospital and the Univeristy of California, 94110, USA.
Greenberg
M B
MB
Darney
P D
PD
D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects / Q000493:pharmacokinetics; D000021:Abortifacient Agents, Steroidal; D000027:Abortion, Incomplete / Q000188:drug therapy; D000028:Abortion, Induced / Q000379:methods*; D000030:Abortion, Missed / Q000188:drug therapy; D020070:Cervical Ripening / Q000187:drug effects; D004359:Drug Therapy, Combination; D036262:Empirical Research; D005260:Female; D033161:Government Regulation; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D008727:Methotrexate; D015735:Mifepristone; D016595:Misoprostol / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020331:Mobius Syndrome / Q000139:chemically induced; D010120:Oxytocics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006473:Postpartum Hemorrhage / Q000188:drug therapy; D011247:Pregnancy; D037841:Pregnant People
D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D010120:Oxytocics; D016595:Misoprostol; D015735:Mifepristone; D008727:Methotrexate